<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-03-18">18 March 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Maurizio</forename><surname>Cutolo</surname></persName>
							<email>mcutolo@unige.it</email>
							<affiliation key="aff0">
								<orgName type="laboratory">Research Laboratories and Academic Division of Clinical Rheumatology</orgName>
								<orgName type="institution">University of Genova</orgName>
								<address>
									<settlement>Genova</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Hopp</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Mundipharma Research GmbH &amp; Co. KG</orgName>
								<address>
									<settlement>Limburg, Hessen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Liebscher</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Mundipharma Research GmbH &amp; Co. KG</orgName>
								<address>
									<settlement>Limburg, Hessen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bhaskar</forename><surname>Dasgupta</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Southend University Hospital</orgName>
								<address>
									<addrLine>Westcliff-on-Sea</addrLine>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Buttgereit</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-03-18">18 March 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">5F9F18CD49C7E489EC08188CA651A62B</idno>
					<idno type="DOI">10.1136/rmdopen-2016-000426</idno>
					<note type="submission">Received 22 December 2016 Revised 22 February 2017 Accepted 24 February 2017 For numbered affiliations see end of article.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cutolo M</term>
					<term>Hopp M</term>
					<term>Liebscher S</term>
					<term>et al. Modifiedrelease prednisone for polymyalgia rheumatica: a multicentre</term>
					<term>randomised</term>
					<term>active-controlled</term>
					<term>double-blind</term>
					<term>parallel-group study. RMD Open 2017;3: e000426</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective: To assess the efficacy and safety of modified-release (MR) versus immediate-release (IR) prednisone in newly diagnosed glucocorticoid (GC)naïve patients with polymyalgia rheumatica (PMR).</s></p><p><s>Methods: Patients were randomised to double-blind MR prednisone (taken at approximately 22:00) or IR prednisone (taken in the morning), 15 mg/day for 4 weeks.</s><s>The primary end point was complete response rate (≥70% reduction in PMR visual analogue scale, duration of morning stiffness and C reactive protein (CRP) (or CRP &lt;2× upper limit of normal (ULN))) at week 4. Non-inferiority was decided if the lower 95% confidence limit (MR vs IR prednisone) was above −15%.</s><s>400 patients were planned but only 62 were enrolled due to difficulties in recruiting GCnaïve patients with PMR with CRP ≥2×ULN.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p><s>The percentage of complete responders at week 4 was numerically greater for MR prednisone (53.8%) than for IR prednisone (40.9%).</s><s>Noninferiority of MR versus IR prednisone was not proven in the primary analysis on the per protocol population (N=48; treatment difference: 12.22%; 95% CI −15.82% to 40.25%).</s><s>However, sensitivity analysis on the full analysis population showed an evident trend favouring MR prednisone (N=62; treatment difference: 15.56%; 95% CI −9.16% to 40.28%).</s><s>Adverse events were generally mild and transient with no unexpected safety observations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions:</head><p><s>The study showed a clear trend for favourable short-term efficacy of MR prednisone versus IR prednisone in early treatment of PMR.</s><s>Further studies are warranted.</s></p><p><s>Trial registration number: EudraCT number 2011-002353-57; Results.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease of older people <ref type="bibr" target="#b2">1</ref> characterised by new-onset bilateral shoulder and/or hip girdle pain with pronounced stiffness and an acute phase response. <ref type="bibr">2 3</ref></s><s>Glucocorticoids (GCs) are the mainstay of treatment and rapidly improve PMR symptoms; <ref type="bibr" target="#b5">4</ref> an initial flexible minimum effective GC dose of 12.5-25 mg prednisone (recognising demographics, comorbidities, comedications, GC risk factors and disease severity) is recommended by the 2015 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) guidelines. <ref type="bibr">5 6</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key messages</head><p><s>What is already known about this subject?</s></p><p><s>▸ Optimising the timing of glucocorticoid (GC)  administration in relation to endogenous cortisol rhythms and symptom severity using modifiedrelease (MR) formulations can improve therapeutic potential in inflammatory conditions, as already demonstrated in rheumatoid arthritis.</s><s>▸ Preliminary studies suggest that MR prednisone may also have benefits in polymyalgia rheumatica (PMR), but data from randomised controlled trials are lacking.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>What does this study add?</head><p><s>▸ This randomised controlled study showed a clear trend for a larger reduction in key PMR symptoms and levels of pro-inflammatory cytokine interleukin (IL)-6 with MR prednisone compared with immediate-release (IR) prednisone, although only 62 of a planned 400 patients were enrolled due to difficulties in recruiting GC-naïve patients with PMR and the study did not meet its primary objective of showing non-inferiority.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>How might this impact on clinical practice?</head><p><s>▸ Results from this study, though limited, suggest favourable efficacy of MR prednisone over IR prednisone in patients with PMR, and further confirmation should be sought from larger clinical trials.</s><s>▸ Experience from this study demonstrates that careful consideration of PMR inclusion and response criteria is required.</s></p><p><s>]<ref type="bibr" target="#b12">[9]</ref><ref type="bibr" target="#b13">[10]</ref> Modified-release (MR) prednisone has been developed to optimise oral GC treatment strategies with respect to circadian rhythms of inflammation by releasing prednisone ∼4 hours after the administration of the tablet in the late evening.</s><s>]<ref type="bibr" target="#b15">[12]</ref> Preliminary studies in PMR suggest that MR prednisone may also have benefits in this inflammatory condition. <ref type="bibr" target="#b16">13</ref></s><s>his randomised, double-blind, active-controlled, parallel-group, non-inferiority phase III clinical study aimed to assess the efficacy and safety of evening MR prednisone compared with morning administration of immediate-release (IR) prednisone in newly diagnosed patients initiating GC treatment for PMR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Setting, patients and treatments</head><p><s>The study (EudraCT number 2011-002353-57) was conducted between March 2013 and March 2014 at 41 secondary care centres across nine European countries.</s><s>Patients aged ≥50 years, newly diagnosed with PMR and previously untreated with GCs for PMR, were eligible for inclusion.</s><s>According to the 2012 EULAR/ACR provisional classification criteria for PMR, <ref type="bibr">14 15</ref> the diagnosis had to be confirmed by all of the following at screening: (1) new-onset bilateral shoulder pain with/without hip girdle pain; (2) a PMR visual analogue scale (VAS) score ≥50 (0-100 scale); (3) duration of morning stiffness &gt;45 min and (4) acute phase response shown by elevated C reactive protein (CRP; ≥2 times the upper limit of normal (ULN)).</s><s>Patients were randomised in a 1:1 ratio to MR or IR prednisone for 4 weeks, and received 15 mg IR prednisone/placebo between 5:00 and 9:00 and 15 mg MR prednisone/placebo at 22:00±30 min.</s><s>No rescue medication was used, and other medications for the treatment of PMR, including analgesics and coanalgesics, were prohibited during the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study assessments</head><p><s>Every morning and evening, patients completed an electronic diary (Log Pad, PHT Corporation), recording how their PMR had affected them (PMR VAS), their overall pain (global pain VAS), pain in their arms and shoulders (shoulder pain VAS), their overall level of fatigue/tiredness (fatigue VAS), duration of morning stiffness and time of medication intake.</s><s>Interleukin-6 (IL-6), CRP and erythrocyte sedimentation rate (ESR) were measured at baseline, week 1 (CRP/ESR only) and week 4. Adverse events (AEs) were recorded throughout the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>The primary objective was to demonstrate non-inferiority of MR prednisone administered in the evening versus IR prednisone administered in the morning, with regard to the percentage of complete responders at week 4 ( primary end point).</s><s>Complete response was defined as ≥70% improvement from baseline in PMR VAS, duration of morning stiffness and CRP (or CRP &lt;2×ULN)). <ref type="bibr" target="#b19">16</ref></s><s>The primary end point was analysed using logistic regression with treatment as a factor and baseline PMR VAS score, duration of morning stiffness and CRP as covariates.</s><s>Non-inferiority was concluded if the lower limit of the two-sided 95% CI was above −15%.</s></p><p><s>The primary analysis was performed using the per protocol population (PPP) with sensitivity analysis performed using the full analysis population (FAP; all randomised patients who received ≥1 dose of study treatment).</s><s>Assuming a complete response rate of 69% <ref type="bibr" target="#b19">16</ref> in the comparator arm at week 4, an expected treatment difference of 0%, a non-inferiority bound of −15%, 80% power and a two-sided α of 0.05, a sample size of 300 patients in the PPP (∼400 randomised patients) was required.</s><s>Further methodology can be found in the online supplementary material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study patients</head><p><s>The study enrolled, randomised and treated 62 patients (21 male patients, 41 female patients), all Caucasian, with a mean age of 69 years (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s><s>All patients were included in the FAP and safety population, while 48 patients (77.4%) were included in the PPP.</s><s>The study experienced a high screen failure rate (62/124 patients screened), primarily due to an insufficiently high CRP value (77% of screen failures did not have CRP ≥2×ULN).</s><s>The difficulties in recruiting GC-naïve patients with PMR fulfilling the inclusion criteria, and cessation of production of the comparator Decortin 1 mg tablets, led to the premature termination of the study after 11 months' recruitment.</s><s>Participant flow is shown in figure <ref type="figure" target="#fig_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary end point</head><p><s>The percentage of complete responders at week 4 was numerically higher for MR prednisone (53.8%) than for IR prednisone (40.9%, table 1), although non-inferiority of MR versus IR prednisone was not proven in the primary PPP analysis (treatment difference: 12.22% in favour of MR prednisone; 95% CI −15.82% to 40.25%).</s><s>Sensitivity analysis on the FAP showed a trend in favour of MR prednisone (treatment difference: 15.56%; 95% CI −9.16% to 40.28%).</s><s>The study was relevantly underpowered (N=48 vs planned 300 patients in the PPP) due to recruitment difficulties and early study termination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary end points</head><p><s>A clear consistent trend for a larger favourable effect of MR prednisone compared with IR prednisone was observed for all secondary end points (except CRP and ESR) at weeks 1 and 4 (table <ref type="table" target="#tab_1">2</ref>).</s><s>The percentage of responders ( patients with ≥70% improvement from baseline) was also greater for MR prednisone than for IR prednisone at weeks 1 and 4 for all secondary end points (see online supplementary table <ref type="table" target="#tab_1">S2</ref>).</s><s>Clinically significant mean reductions and treatment differences of more than 10 points in favour of MR prednisone were observed for PMR VAS, global pain VAS and shoulder pain VAS (table <ref type="table" target="#tab_1">2</ref>).</s><s>MR prednisone was markedly more effective than IR prednisone in reducing morning stiffness duration from as early as week 1 (mean reduction of 326 vs 160 min, table 2), which was supported by the percentage of responders (44% vs 17%, online supplementary table <ref type="table" target="#tab_1">S2</ref>).</s></p><p><s>MR prednisone indicated good efficacy in reducing IL-6 levels compared with IR prednisone at week 4 (decrease from baseline of −37.4 vs −29.8 pg/mL, table <ref type="table" target="#tab_1">2</ref>).</s><s>Notable reductions in CRP and ESR were observed in both  *Complete response was defined as all three of the following: (1) ≥70% improvement from baseline in the polymyalgia rheumatica visual analogue scale, (2) ≥70% reduction in the duration of morning stiffness and (3) ≥70% reduction in the C reactive protein (CRP) value (or CRP &lt;2× upper limit of normal).</s><s>†Partial response was defined as two of the above three criteria being met.</s><s>treatment groups, with a larger decrease for IR prednisone (although we noted that baseline CRP values were higher in the IR prednisone group, and mean CRP values at week 4 were lower for MR prednisone (8.4 mg/ L) than for IR prednisone (17.9 mg/L)).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The AEs reported during the study are presented in online supplementary table <ref type="table">S3</ref>.</s><s>While more patients experienced AEs in the MR prednisone group (19 (59%); 8 (25%) related) than the IR prednisone group (9 (30%); 3 (10%) related), this was not driven by any specific AEs and the majority of subjects in both treatment groups experienced non-related AEs.</s><s>Two patients experienced serious AEs ( pancytopenia and temporal arteritis), which were not treatment-related.</s><s>Three patients prematurely discontinued due to AEs: upper abdominal pain in the MR prednisone group and temporal arteritis and burning sensation in the IR prednisone group (figure <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In this study, the complete response rate at week 4 was numerically greater with MR prednisone (53.8%) than with IR prednisone (40.9%).</s><s>Non-inferiority of MR prednisone versus IR prednisone was not proven for the primary end point; however, even with only 48 patients in the PPP (vs the 300 planned), the point estimate was clearly in favour of MR prednisone and the lower 95% confidence limit was only marginally below (−15.82%) the decided non-inferiority threshold of −15%.</s><s>Sensitivity analysis on the FAP supported the trend in favour of MR prednisone, and secondary efficacy results were encouraging, showing a clear consistent trend for a stronger effect of MR prednisone compared with IR prednisone.</s><s>Of note, evening MR prednisone was associated with significantly greater reductions in IL-6 levels than morning IR prednisone, suggesting a more effective downregulation of night cytokine synthesis. <ref type="bibr" target="#b20">17</ref></s><s>These results are similar to findings in the CAPRA studies in RA. <ref type="bibr">10 12</ref> Consistent with the CAPRA-1 study, we observed no significant difference between MR prednisone and IR prednisone on other inflammatory markers (CRP and ESR).</s></p><p><s>The study experienced a higher than expected screen failure rate (50%), primarily due to patients demonstrating lower CRP values not fulfilling the strict inclusion criteria when referred.</s><s>It appears that in suspected PMR, primary care practitioners are willing to refer GC-naïve only patients with mild elevation or normal levels of inflammatory markers.</s><s>However, it is likely that this population may contain predominantly noninflammatory PMR mimics. <ref type="bibr" target="#b21">18</ref></s><s>he CAPRA studies have already confirmed that optimising the timing of GC administration improves the benefit:risk ratio of low-dose GC treatment in RA, and the open-label extension of the CAPRA-1 study <ref type="bibr" target="#b14">11</ref> and other publications <ref type="bibr">19 20</ref> confirmed positive long-term effects.</s><s>A recent clinical experimental study further supports the use of chronotherapy in PMR. <ref type="bibr" target="#b12">9</ref> Although the formal criteria of non-inferiority were not met, our study showed a clear trend for a favourable clinical effect of MR prednisone over IR prednisone in patients with PMR.</s><s>Further confirmation should be sought from a large clinical trial in patients with PMR, with careful consideration of inclusion and response criteria, based on the present study experience.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Participant flow.</s></p></div></figDesc><graphic coords="3,217.47,48.42,335.96,340.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Response rates</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="2">Modified-release prednisone</cell><cell cols="2">Immediate-release prednisone</cell></row><row><cell></cell><cell></cell><cell>Per protocol</cell><cell>Full analysis</cell><cell>Per protocol</cell><cell>Full analysis</cell></row><row><cell>Response</cell><cell>Week</cell><cell>population (N=26)</cell><cell>population (N=32)</cell><cell>population (N=22)</cell><cell>population (N=30)</cell></row><row><cell cols="2">Complete response* (n (%)) 1</cell><cell>3 (11.5)</cell><cell>5 (15.6)</cell><cell>4 (18.2)</cell><cell>4 (13.3)</cell></row><row><cell></cell><cell>2</cell><cell>7 (26.9)</cell><cell>9 (28.1)</cell><cell>7 (31.8)</cell><cell>7 (23.3)</cell></row><row><cell></cell><cell>4</cell><cell>14 (53.8)</cell><cell>17 (53.1)</cell><cell>9 (40.9)</cell><cell>10 (33.3)</cell></row><row><cell>Partial response † (n (%))</cell><cell>1</cell><cell>8 (30.8)</cell><cell>8 (25.0)</cell><cell>1 (4.5)</cell><cell>1 (3.3)</cell></row><row><cell></cell><cell>2</cell><cell>11 (42.3)</cell><cell>13 (40.6)</cell><cell>2 (9.1)</cell><cell>2 (6.7)</cell></row><row><cell></cell><cell>4</cell><cell>6 (23.1)</cell><cell>8 (25.0)</cell><cell>3 (13.6)</cell><cell>4 (13.3)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Secondary efficacy results (full analysis population)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="2">Modified-release</cell><cell cols="2">Immediate-release</cell><cell></cell><cell>p Value for</cell></row><row><cell></cell><cell></cell><cell cols="2">prednisone (N=32)</cell><cell cols="2">prednisone (N=30)</cell><cell>Estimate</cell><cell>treatment</cell></row><row><cell>Parameter</cell><cell>Visit</cell><cell>n</cell><cell>Mean (SD) †</cell><cell>n</cell><cell>Mean (SD) †</cell><cell>(95% confidence limit)*</cell><cell>difference</cell></row><row><cell>PMR VAS (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>80.7 (12.88)</cell><cell>30</cell><cell>81.0 (11.70)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>31</cell><cell>−37.1 (25.70)</cell><cell>30</cell><cell>−28.2 (27.55)</cell><cell>−9.3 (−22.97 to 4.30)</cell><cell>0.176</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−70.4 (20.81)</cell><cell>23</cell><cell>−59.8 (24.02)</cell><cell>−12.8 (−22.58 to −3.05)</cell><cell>0.011</cell></row><row><cell>PMR VAS at awakening (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>81.7 (17.26)</cell><cell>30</cell><cell>85.9 (9.68)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>32</cell><cell>−36.6 (29.40)</cell><cell>30</cell><cell>−29.4 (29.78)</cell><cell>−10.9 (−25.45 to 3.61)</cell><cell>0.138</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−70.7 (18.72)</cell><cell>23</cell><cell>−63.7 (23.25)</cell><cell>−11.6 (−21.33 to −1.79)</cell><cell>0.021</cell></row><row><cell>Duration of morning stiffness (minutes)</cell><cell>Baseline</cell><cell>32</cell><cell>530 (531.0)</cell><cell>30</cell><cell>616 (591.0)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>31</cell><cell>−326 (435.3)</cell><cell>30</cell><cell>−160 (412.4)</cell><cell>134.5 (18.50 to 250.50) ‡</cell><cell>0.021</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−457 (517.9)</cell><cell>23</cell><cell>−417 (574.7)</cell><cell>46.9 (−110.00 to 203.83) ‡</cell><cell>0.592</cell></row><row><cell>Global pain VAS (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>80.0 (13.14)</cell><cell>30</cell><cell>78.2 (13.96)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>31</cell><cell>−36.2 (26.73)</cell><cell>30</cell><cell>−27.1 (27.96)</cell><cell>−7.5 (−21.10 to 6.11)</cell><cell>0.275</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−68.7 (21.73)</cell><cell>23</cell><cell>−55.5 (25.55)</cell><cell>−13.6 (−23.23 to −3.26)</cell><cell>0.011</cell></row><row><cell>Global pain VAS at awakening (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>80.6 (18.94)</cell><cell>30</cell><cell>83.4 (13.13)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>32</cell><cell>−35.2 (30.03)</cell><cell>30</cell><cell>−28.5 (32.46)</cell><cell>−9.1 (−23.78 to 5.57)</cell><cell>0.219</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−69.3 (20.67)</cell><cell>23</cell><cell>−60.9 (28.28)</cell><cell>−12.3 (−23.23 to −1.42)</cell><cell>0.028</cell></row><row><cell>Shoulder pain VAS (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>81.0 (13.31)</cell><cell>30</cell><cell>79.9 (13.01)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>31</cell><cell>−36.9 (26.85)</cell><cell>30</cell><cell>−28.4 (28.67)</cell><cell>−7.4 (−21.55 to 6.66)</cell><cell>0.295</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−68.4 (21.46)</cell><cell>23</cell><cell>−57.7 (25.92)</cell><cell>−11.1 (−21.30 to −0.91)</cell><cell>0.033</cell></row><row><cell>Fatigue VAS (0-100 scale)</cell><cell>Baseline</cell><cell>32</cell><cell>72.9 (19.31)</cell><cell>30</cell><cell>75.7 (14.31)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>31</cell><cell>−29.8 (24.94)</cell><cell>30</cell><cell>−24.6 (27.66)</cell><cell>−7.8 (−20.67 to 5.07)</cell><cell>0.230</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−59.4 (27.34)</cell><cell>23</cell><cell>−57.6 (23.16)</cell><cell>−6.4 (−16.76 to 4.05)</cell><cell>0.225</cell></row><row><cell>C reactive protein (mg/L)</cell><cell>Baseline</cell><cell>32</cell><cell>50.6 (32.34)</cell><cell>30</cell><cell>69.6 (49.38)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>30</cell><cell>−40.8 (27.46)</cell><cell>30</cell><cell>−48.9 (44.27)</cell><cell>−6.2 (−13.61 to 1.22)</cell><cell>0.100</cell></row><row><cell></cell><cell>Week 4</cell><cell>27</cell><cell>−44.0 (32.24)</cell><cell>23</cell><cell>−52.9 (48.33)</cell><cell>−8.0 (−16.37 to 0.37)</cell><cell>0.060</cell></row><row><cell>Erythrocyte sedimentation rate (mm/hour)</cell><cell>Baseline</cell><cell>32</cell><cell>66.5 (21.62)</cell><cell>30</cell><cell>68.3 (22.84)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 1</cell><cell>29</cell><cell>−25.8 (17.03)</cell><cell>35</cell><cell>−23.9 (15.29)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 4</cell><cell>31</cell><cell>−38.8 (24.14)</cell><cell>25</cell><cell>−40.1 (23.65)</cell><cell>Not estimable §</cell><cell></cell></row><row><cell>Interleukin-6 (pg/mL)</cell><cell>Screening</cell><cell>28</cell><cell>41.4 (34.97)</cell><cell>30</cell><cell>40.9 (35.18)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Week 4</cell><cell>19</cell><cell>−37.4 (41.27)</cell><cell>22</cell><cell>−29.8 (32.61)</cell><cell>−6.5 (−11.84 to −1.23)</cell><cell>0.017</cell></row><row><cell cols="5">Larger decreases from baseline represent a favourable treatment effect for all secondary efficacy end points.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">*Estimates are least square means with confidence limits from a repeated measures analysis of covariance model, if not stated otherwise.</cell><cell></cell><cell></cell></row><row><cell cols="4">†Raw mean at screening/baseline and mean change from baseline at weeks 1 and 4.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">‡Estimates and confidence limits stem from the Hodges-Lehmann method.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>§Convergence criteria not met.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">PMR, polymyalgia rheumatica; VAS, visual analogue scale.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The authors would like to thank all the study investigators and participants and members of the study team from Mundipharma Research GmbH &amp; Co. KG.</s><s>Karen Mower (Scientific Editor) provided medical writing assistance that was funded by Mundipharma Research Limited.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Contributors MC, MH, BD and FB were involved in the development of study protocol.</s><s>MC, BD and FB were involved in patient recruitment and data acquisition.</s><s>SL was involved in data analysis.</s><s>MC, MH, SL, BD and FB were involved in manuscript preparation and approved the final version of the manuscript.</s></p><p><s>Funding The investigation was supported by Mundipharma Research Limited.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p><s>The Independent Ethics Committee of each centre reviewed and approved the protocol, and written informed consent was obtained from all patients before enrolment.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data sharing statement No additional data are available.</head><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http:// creativecommons.org/licenses/by-nc/4.0/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-000426</idno>
		<idno>10.1136/rmdopen-2016-000426 on 18</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen:firstpublishedas10.1136/rmdopen-2016-000426on18" />
	</analytic>
	<monogr>
		<title level="m">RMD Open on May 17, 2022 by guest</title>
				<imprint>
			<date type="published" when="2017-03">2017. March 2017. May 17. March 2017</date>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e000426</biblScope>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-000426RMD</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen:firstpublishedas10.1136/rmdopen-2016-000426on18" />
	</analytic>
	<monogr>
		<title level="j">Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e000426</biblScope>
			<date type="published" when="2017-03">2017. May 17. March 2017</date>
		</imprint>
	</monogr>
	<note>Downloaded from REFERENCES</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part II</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Helmick</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.23176</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="26" to="35" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica and giant-cell arteritis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boiardi</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMra011913</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page" from="261" to="271" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Giant-cell arteritis and polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Weyand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Goronzy</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-139-6-200309160-00015</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="505" to="515" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Treatment of polymyalgia rheumatica: a systematic review</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hernández-Rodríguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Cid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>López-Soto</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinternmed.2009.352</idno>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="1839" to="1850" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-0004265</idno>
	</analytic>
	<monogr>
		<title level="j">Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e000426</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<idno type="DOI">10.1136/rmdopen-2016-000426on18</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen" />
		<title level="m">Vasculitis on May 17, 2022 by guest. Protected by copyright</title>
				<imprint>
			<date type="published" when="2017-03">March 2017</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dejaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perel</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-207492</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1799" to="1807" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dejaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perel</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.39333</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheumatol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2569" to="2580" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">More night than daycircadian rhythms in polymyalgia rheumatica and ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Spies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Straub</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.091283</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="894" to="899" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">How should impaired morning function in rheumatoid arthritis be treated?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<idno type="DOI">10.3109/03009742.2011.566438</idno>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol Suppl</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="28" to="39" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Galbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kall</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13075-016-1072-4</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">174</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised, controlled trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Doering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schaeffler</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(08)60132-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="205" to="214" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Doering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schaeffler</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.126888</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1275" to="1280" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kirwan</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-201067</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="204" to="210" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica has a nocturnal rise in serum interleukin-6 which is almost completely suppressed by nighttime prednisone</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zakout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kirwan</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.20347</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">79</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maradit-Kremers</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-200329</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="484" to="492" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maradit</forename><surname>Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
		<idno type="DOI">10.1002/art.34356</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="943" to="954" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Patientreported outcomes in polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Matteson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maradit-Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.110977</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="795" to="803" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Straub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Glück</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/39.6.624</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="624" to="631" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica: the mess we are now in and what we need to do about it</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hutchings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Matteson</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.22106</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="518" to="520" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Pfeiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krenzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dockhorn</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00296-012-2583-1</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatol Int</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1447" to="1454" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Iaccarino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Doria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="498" to="505" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-000426</idno>
	</analytic>
	<monogr>
		<title level="j">Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e000426</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><surname>Rmd Open On</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-000426on18</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen" />
		<imprint>
			<date type="published" when="2017-03">May 17. March 2017</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
